and but not single nucleotide polymorphisms correlate with response to chemotherapy in endometrial carcinoma.

Our study aimed to investigate the correlation between single nucleotide polymorphisms of genes and postoperative chemotherapy efficacy and prognosis of endometrial carcinoma. Our study included 108 patients with endometrial carcinoma and 100 healthy participants. rs11615/ rs25487/ rs1800975 gene polymorphisms were detected by polymerase chain reaction-restriction fragment length polymorphism. Then the chemotherapy efficacy and toxic effects of the patients were assessed. The genotype and allele frequency of rs11615/ rs25487 in the case group were significantly different from that in the control group (all <0.05). The patients with AA + GA in rs11615 had an increased risk of endometrial carcinoma than those with GG, and the risk of endometrial carcinoma for patients with AA + GA was also higher in comparison with patients with GG genotype in rs25487 (all <0.05). GG on both rs11615/ rs25487 had a higher effective rate of chemotherapy than GA + AA (all <0.05). rs11615/ rs25487 gene polymorphisms were linked with toxic effects in liver, kidney, and nervous system. rs11615/ rs25487, muscular invasion, and tumor stage were independent risk factors for the prognosis of endometrial carcinoma (all <0.05). However, no significant associations were observed between rs1800975 polymorphism and chemotherapy efficacy and prognosis of endometrial carcinoma (all >0.05). These results indicated that and but not polymorphisms correlate with response to chemotherapy in endometrial carcinoma.